Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Injections × NET × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 10 Thoracic 2 Gastrointestinal 2 Breast 2 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 Other 1 NET 1 Myeloid 1 Lymphoid 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 Endocrine 1 Dermatologic 1 Classical hematology 1 CNS 1

Conditions

Neuroendocrine Tumors 4 Adenoma, Islet Cell 2 Tuberous Sclerosis 1 Neoplasms 1 Gastroenteropancreatic Neuroendocrine Tumors 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Carcinoid Tumor 1

Interventions

Everolimus 5 Sunitinib 4 lutetium Lu 177 dotatate 2 PM 01183 2 Octreotide 2 Doxorubicin 2 telotristat ethyl 1 repotrectinib 1 pralsetinib 1 pasireotide 1 motesanib diphosphate 1 epothilone B 1 dactolisib 1 copper dotatate CU-64 1 batifiban 1 avelumab 1 Surveys and Questionnaires 1 SNX-5422 1 Referral and Consultation 1 Radiomics 1 Oxaliplatin 1 Lutetium-177 1 Lutetium 1 Leucovorin 1 Irinotecan 1 Injections 1 Fluorouracil 1 Embolization, Therapeutic 1 Cytidine Triphosphate 1 Chemoembolization, Therapeutic 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04837885 2025-07-23

LUTARTERIAL

University Hospital, Bordeaux

Phase 2 Recruiting

Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡